Literature DB >> 26998901

Early Prediction of Hypertensive Disorders of Pregnancy Using Cell-Free Fetal DNA, Cell-Free Total DNA, and Biochemical Markers.

Shin Young Kim1, Hyun Jin Kim, So Yeon Park, Yoo Jung Han, June Seek Choi, Hyun Mee Ryu.   

Abstract

OBJECTIVE: To evaluate the predictive value of separate and combined tests using cell-free fetal DNA (cffDNA), cell-free total DNA (cfDNA), and biochemical markers for the early detection of pregnancies with hypertensive disorders.
METHODS: A nested case-control study was conducted with 135 singleton pregnancies including 17 gestational hypertension cases, 34 preeclampsia (PE) cases, and 84 controls. We performed real-time quantitative PCR to measure levels of DSCR3 and RASSF1A as cffDNA markers and HYP2 as a cfDNA marker in the first and early second trimesters. Levels of pregnancy-associated plasma protein A (PAPP-A), α-fetoprotein, β-human chorionic gonadotropin, unconjugated estriol, and inhibin A were also determined.
RESULTS: Compared with controls, the median levels and multiples of the median (MoM) values of HYP2 were significantly higher in the PE and hypertensive disorders of pregnancy (HDP) groups at 6-14 and 15-23 weeks. Frist-trimester PAPP-A MoM was significantly lower in PE and HDP than in controls. For PE and HDP, the best model included the first-trimester DSCR3, HYP2, and PAPP-A MoM values achieving detection rates of 67 and 58% at a fixed 10% false-positive rate, respectively [area under the receiver operating characteristic curve 0.832 (95% CI 0.689-0.928) for PE; 0.751 (0.607-0.863) for HDP]. DISCUSSION: The study demonstrates the potential utility of combined first-trimester cffDNA, cfDNA, and PAPP-A for the early prediction of PE.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26998901     DOI: 10.1159/000444524

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  15 in total

1.  Cell-Free DNA (cfDNA) Fetal Fraction in Early- and Late-Onset Fetal Growth Restriction.

Authors:  Danila Morano; Stefania Rossi; Cristina Lapucci; Maria Carla Pittalis; Antonio Farina
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

2.  Predictive value of serum pregnancy-associated plasma protein A for patients with ischemic cerebrovascular disease.

Authors:  Shun Wang; Jun Jiang; Chuncheng Qu; Chengwei Wang; Zhaohui Sun
Journal:  J Clin Lab Anal       Date:  2016-11-03       Impact factor: 2.352

3.  The association between fetal fraction and pregnancy-related complications among Chinese population.

Authors:  Yan Jiang; Yidan Zhang; Qin Yang; Dan Zeng; Keyan Zhao; Xin Ma; Wei Yin
Journal:  PLoS One       Date:  2022-07-12       Impact factor: 3.752

4.  Droplet Digital PCR for Non-Invasive Prenatal Detection of Fetal Single-Gene Point Mutations in Maternal Plasma.

Authors:  Elisabetta D'Aversa; Giulia Breveglieri; Effrossyni Boutou; Angeliki Balassopoulou; Ersi Voskaridou; Patrizia Pellegatti; Giovanni Guerra; Chiara Scapoli; Roberto Gambari; Monica Borgatti
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

Review 5.  Inflammation Thread Runs across Medical Laboratory Specialities.

Authors:  Urs Nydegger; Thomas Lung; Lorenz Risch; Martin Risch; Pedro Medina Escobar; Thomas Bodmer
Journal:  Mediators Inflamm       Date:  2016-07-14       Impact factor: 4.711

6.  Systematic review supports the role of DNA methylation in the pathophysiology of preeclampsia: a call for analytical and methodological standardization.

Authors:  A Cirkovic; V Garovic; J Milin Lazovic; O Milicevic; M Savic; N Rajovic; N Aleksic; T Weissgerber; A Stefanovic; D Stanisavljevic; N Milic
Journal:  Biol Sex Differ       Date:  2020-07-06       Impact factor: 5.027

7.  Usefulness and reliability of cell free fetal DNA screening for main trisomies in case of atypical profile on first trimester maternal serum screening.

Authors:  Julie Carrara; Alexandre Vivanti; Jacques C Jani; Adèle Demain; Jean-Marc Costa; Alexandra Benachi
Journal:  J Transl Med       Date:  2019-11-28       Impact factor: 5.531

8.  Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction.

Authors:  Dong Wook Kwak; Shin Young Kim; Hyun Jin Kim; Ji Hyae Lim; Young-Han Kim; Hyun Mee Ryu
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

Review 9.  Novel Epigenetic Biomarkers in Pregnancy-Related Disorders and Cancers.

Authors:  Valentina Karin-Kujundzic; Ida Marija Sola; Nina Predavec; Anamarija Potkonjak; Ema Somen; Pavao Mioc; Alan Serman; Semir Vranic; Ljiljana Serman
Journal:  Cells       Date:  2019-11-18       Impact factor: 6.600

10.  Predictive Performance of Serum β-hCG MoM Levels for Preeclampsia Screening: A Meta-Analysis.

Authors:  Xiao Zhang; Zhao Huangfu; Fangxin Shi; Zhen Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.